MaxCyte (MXCT) News Today GBX 342.22 -0.78 (-0.23%) (As of 03:07 AM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period MaxCyte (LON:MXCT) Shares Up 3.4% - Still a Buy?December 13, 2024 | americanbankingnews.comMaxCyte (LON:MXCT) Shares Up 3.4% - Here's WhyMaxCyte (LON:MXCT) Stock Price Up 3.4% - Should You Buy?December 13, 2024 | marketbeat.comStifel Nicolaus Reaffirms Their Buy Rating on MaxCyte (MXCT)December 11, 2024 | markets.businessinsider.comMaxCyte’s Strategic Growth and Cost Efficiency Drive Buy RatingDecember 9, 2024 | markets.businessinsider.comMaxCyte (MXCT) Initiated with a Buy at Craig-HallumDecember 9, 2024 | markets.businessinsider.comMaxCyte Shares Surge On Boost to Revenue-Growth OutlookDecember 9, 2024 | marketwatch.comMaxCyte Expands Stock Capital Amid Cell Therapy GrowthDecember 4, 2024 | markets.businessinsider.comThis MaxCyte Insider Increased Their Holding In The Last YearNovember 21, 2024 | finance.yahoo.comMaxCyte, Inc. (NASDAQ:MXCT) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comMaxCyte Director Sells Shares Amid Active TradingNovember 6, 2024 | markets.businessinsider.comCraig-Hallum Sticks to Its Buy Rating for MaxCyte (MXCT)November 5, 2024 | markets.businessinsider.comMaxCyte (LON:MXCT) Stock Crosses Below 50 Day Moving Average - Should You Sell?MaxCyte (LON:MXCT) Share Price Passes Below 50 Day Moving Average - Here's What HappenedNovember 1, 2024 | marketbeat.comMaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the companyOctober 30, 2024 | finance.yahoo.comMaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core ChallengesOctober 10, 2024 | finance.yahoo.comMaxCyte (NASDAQ:MXCT) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comMaxCyte director Stanley Erck sells shares worth over $178kOctober 4, 2024 | investing.comMaxCyte, Inc. (LON:MXCT) Insider Sells £185,033.32 in StockOctober 4, 2024 | insidertrades.comMaxCyte (LON:MXCT) Shares Cross Below 50 Day Moving Average of $325.72MaxCyte (LON:MXCT) Stock Crosses Below 50-Day Moving Average of $325.72September 26, 2024 | marketbeat.comTD Cowen Reaffirms Their Buy Rating on MaxCyte (MXCT)September 25, 2024 | markets.businessinsider.comMaxCyte and Kamau Therapeutics sign platform license agreementSeptember 17, 2024 | finance.yahoo.comMaxCyte (LON:MXCT) Shares Cross Below 50 Day Moving Average of $332.41MaxCyte (LON:MXCT) Stock Passes Below Fifty Day Moving Average of $332.41September 6, 2024 | marketbeat.comMaxCyte (LON:MXCT) shareholders have earned a 22% CAGR over the last five yearsAugust 21, 2024 | finance.yahoo.comStratec SE (SRBZF)August 13, 2024 | finance.yahoo.comBuy Rating Affirmed for MaxCyte on Strong SPL Revenue Growth and Solid Financial PositionAugust 7, 2024 | markets.businessinsider.comMaxCyte, Inc. (NASDAQ:MXCT) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | msn.comMaxCyte earnings preview: what to expectAugust 6, 2024 | markets.businessinsider.comMaxCyte (LON:MXCT) Stock Crosses Above 50 Day Moving Average of $338.25MaxCyte (LON:MXCT) Share Price Passes Above Fifty Day Moving Average of $338.25June 8, 2024 | marketbeat.comWith 64% ownership of the shares, MaxCyte, Inc. (LON:MXCT) is heavily dominated by institutional ownersMay 23, 2024 | finance.yahoo.comMaxCyte, Inc. (MXCT) Q1 2024 Earnings Call TranscriptMay 13, 2024 | seekingalpha.comMaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call TranscriptMay 12, 2024 | finance.yahoo.comNotice of Annual General Meeting of Vicore Pharma Holding AB (publ)April 4, 2024 | finance.yahoo.comMaxCyte, Inc. (LON:MXCT) Insider Sells £22,050 in StockApril 3, 2024 | insidertrades.comInsider Selling: MaxCyte, Inc. (LON:MXCT) Insider Sells 5,000 Shares of StockMaxCyte, Inc. (LON:MXCT - Get Free Report) insider John Johnston sold 5,000 shares of the stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of GBX 441 ($5.54), for a total value of £22,050 ($27,680.14).April 2, 2024 | marketbeat.comMaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finance.yahoo.comMaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five yearsMarch 13, 2024 | finance.yahoo.comMaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023March 12, 2024 | finance.yahoo.comMaxCyte earnings: here's what Wall Street expectsMarch 11, 2024 | markets.businessinsider.comMaxCyte Earnings PreviewMarch 11, 2024 | benzinga.comMaxCyte (LON:MXCT) Shares Cross Below Fifty Day Moving Average of $386.32MaxCyte (LON:MXCT) Share Price Passes Below 50-Day Moving Average of $386.32February 16, 2024 | marketbeat.comMaxCyte Inc Announces Cenk Sumen’s Transition and Severance TermsJanuary 27, 2024 | msn.comMaxCyte, Inc.: MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial ResultsJanuary 9, 2024 | finanznachrichten.deMaxCyte says Q4 revenue is expected to be between $15.5M and $15.7MJanuary 8, 2024 | msn.comMaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial ResultsJanuary 8, 2024 | finance.yahoo.comMaxCyte and Lion TCR join hands for Lion TCR's global expansionJanuary 3, 2024 | msn.comLongtime MaxCyte CEO Doug Doerfler to retire; Maher Masoud tapped as successorDecember 12, 2023 | bizjournals.comInsider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT)December 2, 2023 | finance.yahoo.comMaxCyte May Benefit From Potential Gene Therapy ApprovalNovember 27, 2023 | seekingalpha.comMaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding MemberNovember 16, 2023 | finance.yahoo.comMaxCyte, Inc. (LON:MXCT) Analysts Just Cut Their EPS Forecasts SubstantiallyNovember 15, 2023 | finance.yahoo.comMaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.com Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles." And if you’d like to get your hands on this, here you go, the complete breakdown. MXCT Media Mentions By Week MXCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MXCT News Sentiment▼0.470.65▲Average Medical News Sentiment MXCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MXCT Articles This Week▼20▲MXCT Articles Average Week Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 4imprint Group News Today Herald News Today PayPoint News Today Ocean Wilsons News Today Resolute Mining News Today Chesnara News Today Staffline Group News Today Creightons News Today FireAngel Safety Technology Group News Today Arcontech Group News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:MXCT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.